Martin de Kort is Programme Manager Translational Medicine & Drug Development at EATRIS. After obtaining his PhD in bio-organic chemistry at Leiden University, The Netherlands in 2000, he joined Organon working on synthetic heparin conjugates for the treatment of thrombosis (one drug reached PhII). From 2007 he worked as a lead optimisation project manager at Schering-Plough to develop antidiabetic peptides (e.g. novel insulin and incretins). After the merge with Merck in 2009 he co-headed multidisciplinary teams at MSD involved in lead optimisation of small molecules in endocrinology and development of therapeutic biologicals with prolonged duration of action using proprietary technology. After developing EATRIS and its platforms as it is today his prime interest is to match (industry) clients with our infrastructure experts in the most efficient way to start new public-private collaborations.